Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM) — Defensive Interval Ratio
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM) has a Defensive Interval Ratio of 329 days as of September 2024. Defensive assets of TL92.86 Million (cash TL-, short-term investments TL-, receivables TL92.86 Million) cover 329 days of daily cash needs of TL282.05K/day. See how liquid is Oncosem Onkolojik Sistemler Sanayi ve Ti's working capital to evaluate short-term liquidity relative to the company's equity base.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. Defensive Interval Ratio (2020–2023)
This chart shows how Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.'s Defensive Interval Ratio has evolved across 4 annual periods from 2020 to 2023. As of September 2024, the ratio stands at 329 days, meaning defensive assets of TL92.86 Million can fund 329 days of operations without new revenue. See Oncosem Onkolojik Sistemler Sanayi ve Ti balance sheet independence to measure how much of total assets are equity-financed.
Annual Defensive Interval Ratio for Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (2020–2023)
The table below presents the year-by-year Defensive Interval Ratio for Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. from 2020 to 2023, covering 4 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see market value of Oncosem Onkolojik Sistemler Sanayi ve Ti.
| Year | DIR (days) | Defensive Assets (TRY) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2023 | 219 days | TL54.41 Million | TL248.15K/day | TL- | TL- | ▼ -38 days |
| 2022 | 257 days | TL67.86 Million | TL263.73K/day | TL- | TL- | ▼ -24 days |
| 2021 | 281 days | TL33.96 Million | TL120.74K/day | TL- | TL- | ▲ +62 days |
| 2020 | 220 days | TL21.65 Million | TL98.59K/day | TL- | TL- | — |